文献速递消化、代谢与肾脏急症心脑血管急症重症综合管理与镇静镇痛

COVID-19 mRNA疫苗接种后不良事件监测

Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
PubMed 文献 · JAMA · 2021-01-01
一句话结论在mRNA疫苗接种后1-21天与22-42天的对比监测中,未发现预设信号的不良事件关联,但多数结局置信区间较宽。

风险区间为接种第1或第2剂后1-21天,对照区间为接种后22-42天。主要分析显示,缺血性卒中、阑尾炎、急性心肌梗死等事件发生率在风险区间与对照区间无显著差异,未达到预设信号标准;确诊过敏反应发生率分别为每百万剂4.8和5.1。

要点

  • 缺血性卒中风险区间 vs 对照区间发生率为1612 vs 1781/百万 person-years(RR 0.97, 95%CI 0.87-1.08)。
  • 阑尾炎发生率为1179 vs 1345/百万 person-years(RR 0.82, 95%CI 0.73-0.93),急性心肌梗死为935 vs 1030(RR 1.02, 95%CI 0.89-1.18)。
  • 确诊过敏反应发生率为每百万剂BNT162b2 4.8(95%CI 3.2-6.9),mRNA-1273 5.1(95%CI 3.3-7.6),仅描述性分析。
  • 多数结局置信区间较宽,监测仍在进行中,不能排除罕见不良事件。

适用人群与场景

  • 接种BNT162b2或mRNA-1273第1或第2剂后1-21天为风险区间,同日历日接种后22-42天为对照区间。

诊断标准与关键阈值

  • 信号判定标准:1侧P<.0048,以在2年每周分析中将I类错误控制在.05以下。
  • 监测23种严重结局,包括急性心肌梗死、贝尔麻痹、脑静脉窦血栓、吉兰-巴雷综合征、心肌炎/心包炎、肺栓塞、卒中、血栓伴血小板减少综合征;过敏反应等4种结局仅描述性分析。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 主要终点:风险区间(1-21天)与对照区间(22-42天)严重结局发生率比较,采用泊松回归调整年龄、性别、种族/民族、健康计划和日历日。
  • 关键结果:缺血性卒中1612 vs 1781/百万person-years(RR 0.97, 95%CI 0.87-1.08);阑尾炎1179 vs 1345(RR 0.82, 95%CI 0.73-0.93);急性心肌梗死935 vs 1030(RR 1.02, 95%CI 0.89-1.18)。
  • 无疫苗-结局关联达到预设信号标准;确诊过敏反应每百万剂BNT162b2 4.8(95%CI 3.2-6.9),mRNA-1273 5.1(95%CI 3.3-7.6)。

证据类型、等级与局限

  • 证据类型:基于行政数据和病历回顾的主动监测期中分析,非随机对照试验。
  • 局限:期中分析,多数结局置信区间宽,监测持续进行;仅描述性分析部分结局;未提及证据等级分级。

对床旁实践的改变

  • 支持在急诊/ICU遇到接种mRNA疫苗后1-21天内出现严重事件时,不常规归因于疫苗,但需结合个体情况评估。
  • 过敏反应发生率极低(每百万剂约5例),接种后急性过敏仍需按常规处理。
  • 不改变对罕见不良事件的警惕,因置信区间宽且监测未完成。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Safety surveillance of vaccines against COVID-19 is critical to ensure safety, maintain trust, and inform policy.

OBJECTIVES: To monitor 23 serious outcomes weekly, using comprehensive health records on a diverse population.

DESIGN, SETTING, AND PARTICIPANTS: This study represents an interim analysis of safety surveillance data from Vaccine Safety Datalink. The 10 162 227 vaccine-eligible members of 8 participating US health plans were monitored with administrative data updated weekly and supplemented with medical record review for selected outcomes from December 14, 2020, through June 26, 2021.

EXPOSURES: Receipt of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) COVID-19 vaccination, with a risk interval of 21 days for individuals after vaccine dose 1 or 2 compared with an interval of 22 to 42 days for similar individuals after vaccine dose 1 or 2.

MAIN OUTCOMES AND MEASURES: Incidence of serious outcomes, including acute myocardial infarction, Bell palsy, cerebral venous sinus thrombosis, Guillain-Barré syndrome, myocarditis/pericarditis, pulmonary embolism, stroke, and thrombosis with thrombocytopenia syndrome. Incidence of events that occurred among vaccine recipients 1 to 21 days after either dose 1 or 2 of a messenger RNA (mRNA) vaccine was compared with that of vaccinated concurrent comparators who, on the same calendar day, had received their most recent dose 22 to 42 days earlier. Rate ratios (RRs) were estimated by Poisson regression, adjusted for age, sex, race and ethnicity, health plan, and calendar day. For a signal, a 1-sided P < .0048 was required to keep type I error below .05 during 2 years of weekly analyses. For 4 additional outcomes, including anaphylaxis, only descriptive analyses were conducted.

RESULTS: A total of 11 845 128 doses of mRNA vaccines (57% BNT162b2; 6 175 813 first doses and 5 669 315 second doses) were administered to 6.2 million individuals (mean age, 49 years; 54% female individuals). The incidence of events per 1 000 000 person-years during the risk vs comparison intervals for ischemic stroke was 1612 vs 1781 (RR, 0.97; 95% CI, 0.87-1.08); for appendicitis, 1179 vs 1345 (RR, 0.82; 95% CI, 0.73-0.93); and for acute myocardial infarction, 935 vs 1030 (RR, 1.02; 95% CI, 0.89-1.18). No vaccine-outcome association met the prespecified requirement for a signal. Incidence of confirmed anaphylaxis was 4.8 (95% CI, 3.2-6.9) per million doses of BNT162b2 and 5.1 (95% CI, 3.3-7.6) per million doses of mRNA-1273.

CONCLUSIONS AND RELEVANCE: In interim analyses of surveillance of mRNA COVID-19 vaccines, incidence of selected serious outcomes was not significantly higher 1 to 21 days postvaccination compared with 22 to 42 days postvaccination. While CIs were wide for many outcomes, surveillance is ongoing.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Klein NP, Lewis N, Goddard K, et al. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA. 2021. PMID: 34477808. doi:10.1001/jama.2021.15072

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。